Please login to the form below

Not currently logged in
Email:
Password:

MYSTIC trial

This page shows the latest MYSTIC trial news and features for those working in and with pharma, biotech and healthcare.

Immuno-oncology at ASCO: survival data, combinations and new indications

Immuno-oncology at ASCO: survival data, combinations and new indications

042 trial of Keytruda monotherapy compared to chemotherapy in first-line NSCLC ‘all-comers’. ... AZ won’t be ready to report the much-anticipated OS data from its MYSTIC trial of PD-L1 inhibitor Imfinzi (durvalumab) and CTLA4 inhibitor tremelimumab

Latest news

  • AZ’s immuno-oncology combo fails another lung cancer trial AZ’s immuno-oncology combo fails another lung cancer trial

    AZ’ s immuno-oncology combo fails another lung cancer trial. Latest failure casts doubt on company’s CTLA4 drug. ... PFS in the MYSTIC trial.

  • Merck’s Keytruda scores in frontline lung cancer yet again Merck’s Keytruda scores in frontline lung cancer yet again

    That’s not to say Merck’s position in first-line NSCLC is assured - particularly as the data from the latest trial is still under wraps. ... AZ’s combination of Imfinzi (durvalumab) and tremelimumab missed the PFS endpoint in the MYSTIC trial last

  • AZ pushes back data read-out from MYSTIC lung cancer trial AZ pushes back data read-out from MYSTIC lung cancer trial

    AZ pushes back data read-out from MYSTIC lung cancer trial. The delay could further undermine confidence in a positive outcome. ... AstraZeneca has delayed reporting the overall survival data from its much-anticipated MYSTIC trial of its immuno-oncology

  • AZ bags key lung cancer approval for Imfinzi AZ bags key lung cancer approval for Imfinzi

    The approval is based on the results of the PACIFIC trial, which showed that patients treated with Imfinzi gained an extra 11 months of progression-free survival (PFS) compared to placebo. ... overall survival data from the MYSTIC trial in first-line

  • Merck chalks up another win for Keytruda in lung cancer Merck chalks up another win for Keytruda in lung cancer

    Meanwhile, Bristol-Myers Squibb - which dropped the ball in first-line NSCLC when Opdivo failed a pivotal trial in 2016 - is waiting on the results of its CHECKMATE-227 of ... 1 blocker Opdivo and CTLA4 inhibitor Yervoy (ipilimumab), and AstraZeneca is

More from news
Approximately 1 fully matching, plus 16 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

The gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...

Infographics